[Featured Stock] Curiox Secures 9 out of 10 Global Big Pharma Clients... Supports Next-Generation Cancer Cell Therapy Technology

Cell analysis process automation company Curiox Biosystems is trading higher compared to its IPO price on its first day of listing.

At 9:22 a.m. on the 10th, Curiox was trading at 24,000 KRW, up 85.0% from its IPO price.

Curiox is a medical materials and components company with innovative technology-based product commercialization success, numerous global big pharma clients, and high growth potential following inclusion in the 2024 NIST standardization white paper. The company plans to actively invest the funds raised through its IPO in diversifying customers, expanding GMP facilities in response to increased demand, diversifying new products, and strengthening global sales.

On the 5th of last month, Curiox signed an extension contract with the U.S. National Institute of Standards and Technology (NIST) to participate in the cell analysis standardization consortium and joint research. Curiox will strengthen its support and cooperation system for various cell analysis process automation technologies with NIST, aiming to publish the "2024 Cell Analysis Standardization White Paper."

A Curiox representative said, "Technical collaboration through joint research with NIST has been ongoing since September 2021," adding, "As the publication of the global cell analysis standard white paper accelerates next year, we have signed a two-year extension contract." They further stated, "Once the white paper is published and the standardization recommendations are fully implemented, rapid growth is expected due to high recognition through global standardization."

NIST is a national research institute under the U.S. Department of Commerce that researches various standards in science and industrial technology fields. It selects, develops, and applies national standards for various technologies and measurement techniques needed in industrial sites.

Curiox announced that it has signed a strategic agreement with the Chinese subsidiary of Levity, a leading global life sciences and diagnostics company, for AUTO, a next-generation fully automated cell analysis workflow product. The main points of the strategic collaboration are ▲ the distribution of essential automation solutions for cell analysis from research to clinical stages ▲ expansion of cooperation areas based on the core technologies of both companies and continuous discussions for mutual growth.

Curiox supports the next-generation cancer cell therapy development at the Blood Cancer Innovation Center under the University of Pennsylvania School of Medicine by providing the 'Lamina Wash™' equipment and technology, an accurate and highly reproducible cell analysis process automation platform. The Blood Cancer Innovation Center at the University of Pennsylvania School of Medicine has focused on cutting-edge research related to chronic lymphocytic leukemia (CLL) and lymphoma research and treatment.

Jonghyun Park, a researcher at Daol Investment & Securities, explained, "Curiox has secured 18 out of the top 20 global big pharma companies, including Novartis, GSK, and Gilead, as clients," adding, "It automates the cell analysis process to improve reproducibility and solves issues with centrifugation protocols."

He continued, "Curiox has joined the cell analysis standard consortium involving the U.S. FDA and NIST to establish cell analysis standardization processes," and "It is conducting product performance tests for adoption in commercialized CAR-T therapy production processes."

Nam-yong Kim, CEO of Curiox, said at a pre-listing press conference, "We are the only process automation equipment company participating in the cell analysis standard consortium led by the U.S. NIST and involving the FDA, and we expect the Lamina Wash method to be recommended as a global cell analysis standard technology next year."